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Aging is by far the dominant risk factor for the development of cardiovascular diseases, whose prevalence dramatically increases
with increasing age reaching epidemic proportions. In the elderly, pathologic cellular and molecular changes in cardiac tissue
homeostasis and response to injury result in progressive deteriorations in the structure and function of the heart. Although the
phenotypes of cardiac aging have been the subject of intense study, the recent discovery that cardiac homeostasis during
mammalian lifespan is maintained and regulated by regenerative events associated with endogenous cardiac stem cell (CSC)
activation has produced a crucial reconsideration of the biology of the adult and aged mammalian myocardium. The classical
notion of the adult heart as a static organ, in terms of cell turnover and renewal, has now been replaced by a dynamic model in
which cardiac cells continuously die and are then replaced by CSC progeny differentiation. However, CSCs are not immortal. They
undergo cellular senescence characterized by increased ROS production and oxidative stress and loss of telomere/telomerase
integrity in response to a variety of physiological and pathological demands with aging. Nevertheless, the old myocardium
preserves an endogenous functionally competent CSC cohort which appears to be resistant to the senescent phenotype occurring
with aging. The latter envisions the phenomenon of CSC ageing as a result of a stochastic and therefore reversible cell autonomous
process. However, CSC aging could be a programmed cell cycle-dependent process, which affects all or most of the endogenous
CSC population. The latter would infer that the loss of CSC regenerative capacity with aging is an inevitable phenomenon that
cannot be rescued by stimulating their growth, which would only speed their progressive exhaustion. The resolution of these
two biological views will be crucial to design and develop effective CSC-based interventions to counteract cardiac aging not
only improving health span of the elderly but also extending lifespan by delaying cardiovascular disease-related deaths.
1. Introduction
Over the last decades, average life expectancy has signifi-
cantly increased worldwide although several chronic diseases
continue to grow, with aging as their main risk factor [1].
Aging is a natural and inevitable degenerative process of
biological functions characterized by the progressive decline
in tissue and organ homeostasis and function. Despite the
significant improvements in diagnosis and treatment, the
majority of individuals older than 65 years of age suffer from
an elevated risk to develop cardiovascular diseases (CVDs),
with a decline in the quality of life and in the ability to
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perform the normal activities of daily living [1]. Aging pro-
duces numerous changes in the human heart at structural,
molecular, and functional levels [2]. The most significant
age-related alterations in the heart are left ventricular (LV)
hypertrophy, fibrosis, denervation, and maladaptive remod-
elling that most frequently lead to diastolic dysfunction and
heart failure with preserved ejection fraction [2, 3].
Nowadays, one of the central aims of cardiovascular
research is to uncover the mechanisms that lead to the
age-associated CVDs. One of the most studied phenomena
occurring with aging is the change in the redox state occur-
ring between the embryonic life and the postnatal life
whereby similar metabolic changes have been found then to
occur in the progression from the adult to the aged myocar-
dium. During the embryonic life and the foetal life, cardio-
myocyte (CM) formation and proliferation are the main
mechanisms underlying cardiac contractile muscle develop-
ment. The latter process takes place in a hypoxic environ-
ment characterized by a low reactive oxygen species (ROS)
levels and by an anaerobic metabolism, which are the major
energy source for myocardial cell maintenance [4]. Postnatal
normoxia increases ROS levels producing oxidative stress that
leads to cell cycle exit and terminal differentiation of CMs [5].
In the adult heart, oxidative stress induced by normoxia can
further modulate cardiac function causing overtime heart
decompensation [6]. Thus, the oxidative state and cell metab-
olism have been recognized as important determining factors
for cell fate and cell cycle status in the heart [6].
The inevitable decline of life with aging has been related
to two pivotal mechanisms: an aging telomere-dependent
phenomenon that leads to telomere attrition and an aging
telomere-independent process. The latter that anyway may
also result in telomere attrition is secondary to the alteration
in the intracellular redox state and promotion of oxidative
modification of regulatory molecules and contractile proteins
[7, 8]. Particularly, in the heart, the oxidative stress directly
affects cardiomyocyte (CM) contraction [7, 8] leading to
altered cellular homeostasis that finally promotes a progres-
sive cardiac dysfunction. This condition fosters the develop-
ment of an aging cardiac myopathy characterized by changes
in the microenvironment and the stimuli on the aged myo-
cardium while the number of CMs decreases as a function
of age [9–12]. In order to compensate for the age-related
modifications, the myocardium increases its muscle mass
by CM hypertrophy, which in the long term however results
in a weakened cardiac function and in fibroblast proliferation
causing myocardial and arterial fibrosis. This prototypical
pathologic cardiac remodelling produces an increase in sup-
raventricular and ventricular arrhythmias [13], and it also
produces a further increase of ROS, a characteristic of the
aged organs [14]. Indeed, ROS are considered a risk factor
for a wide range of diseases in elderly and their role has been
continuously investigated in these years in the field of cardiac
regenerative medicine with the aim to develop applicable
protocols to attenuate their formation and to delay the onset
of cardiac morbidity in the elderly [15].
Despite that, for almost a century and until the new mil-
lennium, the adult heart was considered a postmitotic organ,
several recent studies have supported the notion that it
possesses a population of endogenous cardiac stem/progeni-
tor cells (CSCs) supporting myocardial cell turnover and
regeneration due to their intrinsic potential to differentiate
in all cardiac cell lineages [16–23] (Figure 1). This discovery
opened a new era for myocardial regeneration where endog-
enous cardiac stem/progenitor cells were introduced as direct
regenerative agents and/or endogenous targets of regenera-
tive therapy to effectively replenish the heart muscle cells, lost
by injury and/or age, in order to improve/normalize myocar-
dial function [16]. However, the pathological and pathophys-
iological cardiomyopathy that occurs with age also affects the
stem cell microenvironment modifying adult stem cell biol-
ogy and then their ability, during lifespan, to repair damaged
tissues and organs [24–27]. Accordingly, as shown for other
stem cell types [26, 28–31], cardiac stem cell (CSC) potential
has also been found to be compromised or even lost with aging
as a consequence of the accumulation and activation of senes-
cence factors affecting myocardial homeostasis, producing
DNA damage and alteration of the telomere-telomerase sys-
tem eventually leading to a senescent phenotype of CSCs
[32–34]. Despite these evidences, interesting studies have
demonstrated that the old decompensated heart appears to
maintain a functionally competent pool of CSCs during life
and that the senescent phenotype of CSCs may be therefore
reverted using growth factors or cardioprotective molecules
[35–37]. This accumulating knowledge is fundamental for
the prospects of CSCs as main agents for myocardial regener-
ation because the majority of the patients in need of such
therapy are indeed aged subjects.
On this basis, in this review, we will summarize the bio-
logical role of endogenous cardiac stem cells and their impor-
tance in the cardiac tissue maintenance during mammalian
life. We will discuss CSC adaptations and changes in the aged
myocardium and the ability of high-reactivity small mole-
cules to diminish the regenerative potential of the resident
CSC pool inducing a forced entry in a senescent state with
a consequent severe deficit of functionally competent CSCs
with time. We finally will discuss several potential molecular
mechanisms implicated in the preservation of a competent
CSC pool during the lifespan, which could be essential to fos-
ter CSC rejuvenation.
Currently, it is well known that ROS signalling is impor-
tant in the metabolism of embryonic and adult stem cells and
may impact stem cell epigenome and their cell fate [38–40]
but the exact mechanisms of metabolic regulation of stem cell
epigenetics remains still unknown. The importance of redox
signalling in the turnover of adult CSCs is nonetheless one of
the less-explored areas in cardiac regeneration. As stem cells
are considered the most promising tool for regenerative med-
icine, to shed light in this crucial area is a stimulating avenue
for future studies, which will be pivotal to develop new strat-
egies for effective cardiac regeneration medicine with the aim
to prolong the length and quality of human lifespan.
2. Cardiac Tissue Homeostasis Is Maintained by
Endogenous CSC Activation
For many years, cardiovascular diseases, secondary to
age-associated changes in the cardiac tissue, have been
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viewed under the prevalent dogma of the adult heart as a
postmitotic organ composed by a predetermined number of
CMs established at birth and largely preserved throughout
life of the organism until its death [41, 42]. Cardiac growth
that occurs postnatally has been then explained solely by
CM hypertrophy whereby CMs progressively age and enlarge
according with the age of the organism. Based on this pre-
mise, cardiac aging has been considered an autonomous
process leading with time to molecular modifications of the
adult CMs that profoundly alter the characteristics and per-
formance of the heart resulting in a failing cardiomyopathy
[42]. However, this static notion of the adult heart has been
recently questioned by the evidence that, although age is the
major risk and causative factor of the functional maladapta-
tion of the old heart, the chronological age and physical age
do not coincide [43]. Thus, the organism age and organ age
do not proceed at the same rate [43]. Indeed, in the last
decade, it has been reproducibly demonstrated that the adult
mammalian heart maintains a cell turnover during the
organismal life which includes CM replacement and that
the adult heart is able to regenerate after injury through
the activation of the endogenous pool of CSCs [16–23, 35,
37, 44]. This new view has led to the reconsideration of the
mechanisms implicated in the different manifestations of
the aging myopathy with the aim to elucidate CSC contribu-
tion in the homeostasis and in the aging of the heart.
Accordingly, it has been nowadays largely accepted that
the normal homeostasis of the adult heart is balanced by
CM death and regeneration events. In the young heart, the
generation of new CMs contributes significantly to the nor-
mal growth and predominates cell death; on the other hand,
in late adulthood, CM death predominates the formation of
new CMs [37]. However, during cardiac development and
maturation, also the newly formed CMs in the adult life
become terminally differentiated cells after a few rounds of
proliferation; the latter further supports a fundamental role
for CSCs in the maintenance of normal cardiac cellular
homeostasis throughout the life of the organism [45].
Adult stem cells, in the course of the mammalian life, per-
sist mainly in a strictly quiescent state, a property that is cru-
cial for their self-renewal capacity [46–49]. Despite their
quiescence, adult stem cells are empowered with an intrinsic
potential to quickly gain cell cycle competence and to prolif-
erate in order to regenerate their specific tissue, within a lim-
ited time, in response to damage or stress. This requires
metabolic plasticity in order to adapt to either quiescence
or highly proliferative state.
The embryonic, neonatal, and adult mammalian heart
possesses, dispersed throughout its interstitium, the so-called
cardiac stem cells (CSCs) and cardiac progenitor cells (CPCs).
These two populations of stem/progenitor cells are nested
within the myocardium in different states: (1) quiescent and
undifferentiated stem cells that, upon stimulation, are acti-
vated becoming cycling cells to expand the tissue-specific stem
cell compartment of the heart [50–52] and (2) cycling progen-
itor cells that become committed expressing the transcription
factor characteristic of one cardiac cell lineage to generate a
large progeny of differentiated cells [52–54] (Figure 1). CSCs
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Figure 1: Schematic representation of the transitional sequence of cardiac stem cell-committed progeny. Quiescent, primitive,
undifferentiated cardiac stem cells express Oct-4 (pink fluorescence), become activated, and start expressing c-kit (green fluorescence). In
response to stress, these cells multiply and lose expression of Oct-4. The resulting c-kit pos/Oct-4 neg cells are still uncommitted to one
specific cardiac cell lineage. After further expansion and differentiation, the cells induce expression of transcription factors specific to one
cardiac lineage (GATA4, ETS1, or GATA6) and differentiate into one of the three cardiac cell types—cardiomyocytes, endothelial, and
smooth muscle cells—respectively. These newly formed cardiac cells can undergo a few rounds of replication before becoming terminally
differentiated. CSC: cardiac stem cell; vWF-VIII: von Willebrand factor VIII. Figure 1 is reproduced from Georgina M. Ellison et al.,
(under the Creative Commons Attribution License/public domain) [54].
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are indeed clonogenic, self-renewing, and multipotent, giving
rise to a minimum of three different cardiogenic cell lineages
(myocytes, smooth muscle cells, and endothelial cells) both
in vitro and in vivo, andexhibit significant cardiac tissue regen-
erative capacity [54–56] (Figures 1 and 2). These cells, identi-
fied in particular for being c-kit positive and negative for
blood/endothelial markers (Lin-ckitpos CSCs) [55], express
also different and well-characterized membrane markers
(Sca-1, Abcg-2, Flk-1, CD105, CD166, and PDGFR-α) and
transcription factors (Isl-1, Tert, Bmi-1, Gata-4, Mef2c,
Nkx2.5, and Wt-1) [21, 55, 57–61]. Importantly, we recently
demonstrated that a proper and physiological c-kit expression
in the CSC population is necessary for their activation and
survival and their cardiomyogenic differentiation potential
in vitro and in vivo and that a gain-of-function mutation in
the c-kit kinase domain increases CSC’s myogenic and
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Figure 2: c-Kitpos CSCs are multipotent in vitro and in vivo. (a) Undifferentiated c-kitpos (green) CSC-derived cardiospheres express
multipotent stemness markers (c-kit, Oct-4, Sox-2, Klf-4, and Nanog) and Wnt3a (red). Bar = 50 μm. (b) CSC-derived contracting CMs
in vitro express contractile proteins (actinin, cTnI, MHC, and cardiac actin) with coexpression of cardiac transcription factor (Gata-4).
The CSC-derived CMs exhibit well-defined sarcomeric structures (z lines and dots) as well as gap junction formation (Cnx-43) between
cells. DAPI stain nuclei are in blue. Bar = 20μm. (c) Light microscopy image of freshly isolated adult cardiomyocytes from a dissociated
rat heart 28 days after myocardial infarction (MI) and CSC GFP injection (MI +CSC GFP) shows a CSC-derived GFP-positive
cardiomyocyte. (d) Confocal microscopy images show host-derived preexisting GFPneg cardiomyocytes as compared to CSC-derived
GFPpos cardiomyocytes isolated from MI+CSC GFP rat hearts at 28 days after MI. Note that GFPpos cardiomyocytes are of smaller size
and mononucleated when compared to surviving binucleated GFPneg cardiomyocytes of the host. (e) Representative confocal images show
at high magnification a CSC-derived newly formed GFPpos cardiomyocyte in the infarct border zone 28 days after MI treated with CSC
GFP. Figure 2 is reproduced from Carla Vicinanza et al., (under the Creative Commons Attribution License/public domain) [55].
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angiogenic potential in vitro and in vivo [55, 56, 62, 63].On the
other hand, CPCs are immature but already committed myo-
cardial cells that can proliferate and mature into its respective
precursorwhich, in turn, develops into oneof themain cardiac
cell lineages. Thus, CSCs/CPCs are actively involved with car-
diomyocyte turnover, preserving myocyte number, attenuat-
ing the accumulation of hypertrophied CMs, and increasing
the number of newly formed cardiac cells. We repeatedly and
reproducibly demonstrated that in response to different and
diffuse cardiac injuries, endogenous CSCs became activated
to reenter the cell cycle, multiplying themselves to progress
and acquire cardiac lineage commitment and finally differen-
tiate into new CMs among other cardiac cell types [44, 55, 56,
62, 63] (Figure 2). Our results provide the indisputable evi-
dence that CSCs possess cardiomyogenic potential as it would
be expected from true cardiac-specific stem/progenitor cells.
This conclusion is further strengthened by the normal struc-
tural organization and functional activity of CMs generated
in vivo in response to CSC transplantation after cardiac injury
in rodents [44, 55, 62, 63].
CSC-based therapies have been then recently the focus of
most of the preclinical and clinical studies in regenerative
cardiology becoming however the most highly debated topic
of cardiac regeneration. Thus, to fully elucidate the biology of
CSCs, including their senescent phenotype with age, is piv-
otal to develop future reliable approaches in order to manip-
ulate and/or to therapeutically target them in vivo to enhance
and improve their myogenic differentiation potential for car-
diac tissue maintenance or repair in humans.
3. The Impact of Ageing on Endogenous CSCs: A
Theoretical Everlasting Lifespan Limited in
Reality by Cellular Senescence
If cardiac homeostasis is dependent on cell regeneration from
the activation of resident endogenous CSCs, it can be pre-
dicted that the loss of CSC function, either as a consequence
of their death or because they become over time nonproduc-
tive, should result in a progressive decrease in tissue homeo-
stasis [64]. This hypothesis has been tested to explain the
inevitable decompensation that occurs with age in the heart
of simple and more complex organisms producing an
impairment in cell homeostasis and a decline in its regenera-
tive capacity, a process that limits lifespan [37, 65]. It has
been indeed postulated that during aging, the primitive
CSC pool undergoes depletion and/or attenuation in prolif-
eration, and as a result, the heart evolves an inadequate
regenerative response which contributes to the development
of the aging cardiomyopathy [37, 52]. Thus, the critical ques-
tion is whether aging-associated events directly affect the
CSC pool and whether chronological age impacts on the
number and properties of CSCs.
The ability of stem cells to self-renew, as well as their
capacity to differentiate into single or multiple lineages, is
regulated by specific signalling and by their specific niche
organization [66, 67]. Thus, in the past years, many stud-
ies have focused the attention on the importance of the
tissue microenvironment to preserve the primitive pool
of CSCs in the healthy heart [52]. The niche microenvi-
ronment protects stem cells from damaging stimuli [52,
68–70] maintaining their function in tissue homeostasis
[71]. Age-associated disorders in the myocardium are
linked to changes in the cardiac microenvironment and an
impaired or dysregulated communication between the aged
microenvironment and the resident stem/progenitor cells
that leads to a missing activation in response to injury [72].
As a consequence, there are changes in tissue maintenance
whereby, in the absence of their natural milieu, CSCs cannot
preserve their stemness potential and acquire a high proba-
bility to undergo a nonreturn process that leads to the
exhaustion of their compartment [52].
Thus, it has been postulated that a mitotic clock regulates
CSC turnover and their lifespan [73] and that this phenome-
non leads to the development of the aging cardiac myopathy
because cardiac tissue homeostasis changes in function of the
accumulation of older and senescent CSCs [36, 74, 75].
Senescent cells are characterised by an altered gene expres-
sion profile and epigenetic modifications as well as an altered
secretome with release of components which act on adjacent
and distant cells causing fibrosis and inflammation [76–81].
The latter two disorders further impair the adult myocar-
dium as well as its ability to respond adequately to the
increases in physiological loads due to cardiomyocyte num-
ber progressive attrition.
Multiple markers have been utilized for the identifica-
tion of senescent CSCs/CPCs and cardiomyocytes in vitro
and in vivo. In an interesting and elegant work, Castaldi
and colleagues [33] have shown how ageing affects the
functional properties of CSCs comparing c-kit+ CPCs iso-
lated from 3- and 24-month-old wild-type (WT) mice.
CPCs isolated from aged mice display a diminished prolif-
eration rate and stemness potential and differ from those of
young mice in morphology and expression of molecular
markers of senescence. CPCs isolated from aged mice pres-
ent a flattened morphology accompanied by increased
SA-β-Gal and p16 mRNA expression, a dramatic downreg-
ulation of the stemness marker LIN28, and a deficit in car-
diac differentiation potential [33]. We and others have
shown that CSCs/CPCs upregulate cardiac lineage markers
in response to dexamethasone (Dex) treatment in vitro and
that the TGF-β/Wnt/β-catenin pathways are instrumental
to promote CSC differentiation, expansion, and survival
[55, 82–85]. Based on this evidence, Castaldi and colleagues
[33] have compared the response of young and aged CPCs
to Dex treatment, showing that the aged CPCs fail to
upregulate cardiac lineage markers when compared to the
young counterpart. They also investigated the mitochon-
drial activity of CPCs showing that aged CPCs fail to acti-
vate mitochondrial biogenesis and display an increased
expression of proteins involved with oxidative phosphoryla-
tion in response to Dex treatment. Moreover, they found
that the β-catenin and TGF-β gene expression is upregu-
lated in young CPCs in response to Dex treatment whereas
these responses are completely lost in aged CPCs.
The occurrence of senescence markers in cardiac cells
has been explained by two main mechanisms: one telo-
mere dependent and the other telomere independent
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(Figure 3). The telomere-dependent mechanism is a cell
cycle arrest characterized by a process called telomere
shortening [36, 37, 65, 86, 87]. In particular, the ability
of CSCs to produce an infinite number of divisions is a
mechanism tightly controlled by telomeres and telomerase
[88, 89]. The latter restores telomere length after each cell
replication preventing the replicative senescence limit. In
most adult tissues, telomerase activity has been found
insufficient to compensate the progressive telomere attri-
tion that occurs with aging [90]. Taking advantage of the
relatively short mouse lifespan (despite very long telo-
meres), genetically modified mouse models have been used
to study CSC activity during ageing [91–93]. Using a
telomerase-null mice model, it has been reported that the
progressive loss of telomere sequences leads to the loss
of organism viability after 3-6 generations [89]. Moreover,
telomerase-null mice display a profound attenuation in
new CM formation and an increased apoptosis and
hypertrophy of the remaining CMs [89]. The telomere short-
ening process leads overtime to genomic instability, charac-
terized by the expression of senescence markers like the
tumor suppressor p16INK4a [89, 94–96]. p16INK4a expres-
sion is extremely low or practically undetectable in intact via-
ble young cells and tissues but becomes readily apparent in
cells induced to senescence. This protein maintains the
tumor suppressor Rb in a hypophosphorylated active state
inducing cell cycle arrest [97] or initiating apoptosis by
increasing p53 expression via downregulation of Mdm2
[98]. The progressive accumulation of p16INK4a-positive
cells within the aged tissue in vivo [37] might have a dam-
aging influence over neighbouring cells. Baker and col-
leagues [79] have indeed demonstrated, using a transgenic
mouse model characterized by premature tissue senescence
and by a markedly shortened lifespan, that the inducible
elimination of p16INK4a-positive senescent cells delays
the ageing-associated disorders in this mouse model. Thus,
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Figure 3: Schematic representation of the mechanisms implicated with adult stem cell senescence owing to tissue-specific stem/progenitor
cell exhaustion in aging.
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it is expected that the manipulation of the tissue microenvi-
ronment and homeostasis could delay or even revert CSC
dysfunction associated with age.
To assess whether aging of endogenous CSCs is ruled by
an internal cell clock or by a response to the environmental
milieu, we studied the natural aging of CSCs and its effect
on their growth and differentiation in WT mice as compared
to transgenic mice (TG) with CM overexpression of the
insulin-like growth factor-1 (IGF-1) [37]. The expression of
IGF-1 receptors and the synthesis of IGF-1 have been found
attenuated in aged CSCs [37]. The IGF-1/IGF-1 receptor
induces CSC division, upregulates telomerase activity, main-
tains telomere length, hinders replicative senescence, and
preserves the population of functionally competent CSCs.
The IGF-1 pathway has been implicated as a mediator of
CSC senescence whereas increased IGF-1 signalling attenu-
ates ageing-associated markers [37]. At 22 months, ≥70% of
CSCs in WT mice, but only ~10% in the TG mice, are
p16INK4a positive, indicating an increased CSC senescence
and a block in the cell cycle with age. At 22 months, CSC apo-
ptosis is 5-fold higher in WT mice when compared with TG
mice. Concurrently, the decrease in CM number and cardiac
failure in the WT old versus young mice is absent in old TG
mice that show a normal CM number and a normal ventric-
ular performance as compared to their young counterparts.
Therefore, this data provides the proof of concept that with
age, senescence of endogenous CSCs is not regulated by an
internal cell or organismal clock but could be modulated by
the microenvironment with important physiological conse-
quences. These evidences suggest that the aged phenotype
in the CSC population is not irreversible because CSCs can
be rejuvenated and returned to a normal proactive function
in response to appropriate cardiopoietic growth factors [37].
4. Free Radical Theory of Aging:
ROS-Dependent Senescence of
Endogenous CSCs
Despite that the loss of telomere/telomerase integrity is a
major determinant of tissue and organism alteration during
the years [89], aging is mainly caused overtime by a reduced
cellular capacity to respond to stress [99, 100]. Indeed, the
telomere-independent cellular aging, or stress-induced pre-
mature cellular senescence, is promoted by oxidative stress
and/or genetic/epigenetic alterations and oncogene activa-
tion [81, 101–106] (Figure 3).
Nowadays, it has been largely documented that with the
increase of the organismal age and with the occurrence of
cardiac diseases, there is a concomitant increase in the oxida-
tive stress within the tissues [107, 108]. ROS are chemically
reactive molecules including free radicals, oxygen ions, and
peroxides, generated through a variety of extracellular and
intracellular events, in particular by oxidative phosphoryla-
tion in the aerobic metabolism starting from molecular oxy-
gen. ROS activity and concentration are finely controlled by
antioxidant molecules [109]. When excessively produced
and free radical scavenging systems are depleted, ROS can
damage macromolecules [110], affecting cell proliferation
and causing the so-called oxidative stress, defined as a change
in the balance between oxidant and antioxidant elements
[111]. The cardiac work overload that occurs with aging pro-
duces oxidative stress leading to genomic instability and cel-
lular senescence or apoptosis; oxidative stress subsequently
contributes to the development and/or progression of differ-
ent diseases including heart failure [112–115].
ROS can be considered as signalling molecules playing a
major role in the crosstalk between metabolism and stem cell
fate decisions as well as pivotal factors regulating self-rene-
wal, differentiation, and senescence of stem cells [37, 116,
117]. Thus, it is possible that high levels of ROS may lead
to several changes in CSC properties such as partial depletion
of the primitive pool, loss of self-renewing capacity, increased
symmetric division with formation of daughter committed
cells, impaired ability to migrate, and forced entry into a
senescent state. The healthy behaviour and the efficient
regenerative response of the myocardium to wear and tear
and damaging stimuli have been correlated to the low hemo-
dynamic stress that seems to persist within the CSC microen-
vironment, together with O2 gradient within the tissue [36,
52, 118]. Indeed, similarly to embryonic stem cells during
foetal life, the long-term preservation of the adult CSC com-
partment requires a hypoxic milieu in which CSCs are stored
in a quiescent state. The physiological normoxia is necessary
for the activation of CM commitment, and it leads progres-
sively with aging to CSC senescence and its pool exhaustion
[36, 52, 118]. ROS may condition the balance between hyp-
oxia and normoxia in the aged myocardium, influencing
the characteristics of the surrounding milieu of the stem/pro-
genitor cells leading to telomere erosion, formation of
dysfunctional CMs, and a decline in tissue regeneration pro-
cesses [64]. For example, the renin-angiotensin aldosterone
system (RAAS) has been found linked to cardiovascular dis-
ease and age-related declines in cardiac function [119, 120].
The accumulation of Ang II contributes during aging to
chromatin remodelling, DNA damage, and gene expression
activation together with telomere attrition/shortening,
uncapping, and expression of p16INK4a and p53 at a cellular
level. As cited above, all these events have been associated to
cellular senescence and death [121–125]. Thus, the balance
between hypoxic and normoxic conditions in the CSC com-
partment is critical for cardiac homeostasis and for the pres-
ervation of the CSC pool during the lifespan to sustain cell
turnover and the demands of the myocardium. Indeed, a
decrease in ROS levels may improve stem cell maintenance
[126, 127], suggesting that antioxidant enzymes could play
a significant role in the preservation of CSC regenerative
function [128].
Overall, while a link between metabolic rate and the
rate of aging has been provided, it is less clear whether
and how mitochondrial metabolism and ROS are impli-
cated in CSC aging.
5. Evidence for Epigenetic Changes and the
Role of Noncoding RNAs in Cardiac Aging
As above discussed, cardiac aging in mammals can be defined
by definite hallmarks: telomere attrition, mitochondrial
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dysfunction, cellular senescence, stem cell exhaustion, geno-
mic instability, altered intercellular communication, loss of
proteostasis, and deregulated nutrient sensing [78, 129,
130] (Figure 3). Among these alterations, a significant effort
has been recently made in the understanding of the epige-
netic changes leading to aging-related diseases. With aging,
there is an increased transcriptional noise in which a sto-
chastic deregulation of gene expression leads to increased
DNA damage and cellular degeneration and death [131].
Experiments on transcriptional profiling of single CMs iso-
lated from old mice showed considerable variation in tran-
script levels of a panel of heart-specific housekeeping
genes compared to those from young controls [131]. Non-
genetic contributions, which are the alterations secondary
to environmental stimuli or nutrient availability, play a
major role in longevity. Continuous interactions among
genetic/epigenetic and environmental/stochastic factors
influence the possibility to reach the limit of the human
lifespan. Calorie restriction [132], lowering of basal meta-
bolic rate [133], upregulated stress response [134], and
reduced fertility [135] have been shown to correlate with
lifespan extension and to influence the oxidative stress
level. Nevertheless, accumulating evidences have revealed
that genetic differences and somatic mutations also under-
lie longevity, providing a link between aging and genetic
and epigenetic mutations [136]. Epigenetic changes, lead-
ing to impaired biochemical pathways and genetic pro-
cesses [137, 138], have been found to be associated with
cardiac dysfunction and aberrant cardiac regeneration
[139–141]. Furthermore, studies conducted to further the
understanding of the molecular mechanisms underlying
exceptional human longevity also suggest an important
genetic component [142, 143]. In an interesting study con-
ducted in centenarians, a genome-wide methylation analy-
sis has identified genes that are hypo- or hypermethylated
during ageing when compared to those in young people
[144]. Accordingly, genetic/epigenetic variations may pre-
dispose cells to better adapt to cellular stress and to better
survive an adverse environment.
Epigenetic alteration is a heritable alteration in gene
expression or cellular phenotype in organs and tissues in
which DNA, RNA, and proteins are chemically or structur-
ally modified, without changes in their primary sequence.
This phenomenon produces chromatin alteration and influ-
ences gene expression and cell division by regulating access
of the transcriptional machinery to DNA [145]. A large num-
ber of epigenetic alterations occurring with age have been
demonstrated and well characterized and include DNA
methylation and hydroxymethylation, histone modification,
chromatin remodelling, RNA methylation, and the regula-
tion by small and long noncoding RNAs [146–149]. From
yeast to humans, an emerging epigenetic mark in aging cells
is the general loss of histones, which is linked to cell division
[150, 151]. Despite that the loss of histones is the major
determinant of epigenetic alterations, additional important
modifications that occur at a chromatin level are histone
methylation and acetylation [152]. With age, mammalian
cells undergo global DNA hypomethylation and local DNA
hypermethylation [153], a pattern which fits with a global
heterochromatin deregulation and modification influencing
stress tolerance and/or modulating specific pathways.
Many histone modifications are involved in activation or
suppression of genes influencing lifespan. In addition, the
age-dependent altered expression of chromatin-modifying
enzymes could induce epigenetic changes in adult stem
cells resulting in their decline and leading to senescence
[154]. A chromatin-related senescence phenotype has been
found in aged tissues from various organisms, but the real
mechanisms underlying the connection between senes-
cence and longevity are unclear.
Epigenetic and epigenomic modifications occurring dur-
ing aging also dictate stem cell fate. As a typical example, in
the hematopoietic system, the epigenomic modifications
enforce increased self-renewal and decreased differentiation
[155]. The functional potential of hematopoietic stem cells
(HSCs) declines during aging, and it contributes to hemato-
poietic pathophysiology in the elderly and loss of the hema-
topoietic cell pool [156, 157]. Site-specific alterations of
DNA methylation occur at genomic regions associated with
the hematopoietic lineage potential and at target genes
expressed in downstream progenitor and effector cells.
Young HSCs gain DNA methylation on regions associated
with nonhematopoietic lineages, whereas the transition to
old age is marked by gains of DNA methylation at genomic
regions associated with the lymphoid and erythroid lineages
that restrict the potential of old HSCs [156, 157]. In contrast
to young adult HSCs, which showed robust activity in trans-
plantation assays with comparable lineage predisposition and
reconstituting potential, HSCs from old mice showed dimin-
ished repopulating activity lineage potential [156–160]. Beer-
man and colleagues [161] have found that the replicative
decline in HSC and DNA methylation is largely dependent
on the proliferative history of HSCs in a process that appears
to be telomere independent. The evidence that HSC
self-renewal is limited by replicative history may explain
why the loss of HSC quiescence or sustained cycling may lead
to premature HSC exhaustion [162]. Thus, it is possible to
speculate that this evidence could explain the cell exhaustion
that has been shown to exist also in the CSC compartment
with age [52, 162]. Unfortunately, the epigenetic signature
of CPCs is not clearly known, although the epigenetic
mechanisms underlying differentiation of CSCs during
development of the heart have been well documented
[163]. The plasticity and reversibility of DNA methylation
opens the possibility of therapeutically targeting its regula-
tors to restore the function to aged stem cells. Nowadays,
epigenetic aging research is trying to characterize key epi-
genetic steps leading to aging-specific signalling pathway
modification and genetic variants with the aim to restore
them using genetic manipulations, uncovering specific
enzymes for targeted therapeutic strategies to improve life-
span and health span.
Among the environmental and epigenetic factors, there
are a substantial variety of different RNAs that are actively
transcribed from the human genome and have been reported
to be implicated in transcriptional regulation, posttranscrip-
tional gene control, epigenetic control, nuclear genome orga-
nization, and onset of diseases related to aging [164–167].
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Recently, long noncoding (lnc) RNA has emerged as a crucial
class of regulatory molecules responsible for specialized
biological processes during cardiac development, pluripo-
tency, cell fate determination, homeostasis, and disease
[168, 169]. Cardiomyopathy has been associated with a
reduced expression of Mhrt which is a lncRNA that tar-
gets the chromatin-modifying protein complexes [170].
Up to now, the role of lncRNAs in cardiac cells and in
the ageing of cardiac tissue has not been specifically inves-
tigated. However, a number of lncRNAs have been identi-
fied to be important in the processes involved with ageing
such us cellular senescence that in cardiomyocytes is asso-
ciated with multiple cellular processes, for example, ROS
production by mitochondria [171].
Abdelmohsen and colleagues [172] used RNA sequenc-
ing to compare transcripts expressed in proliferating cells
and terminally arrested cells identifying lncRNAs involved
in cellular senescence [172]. They found Malat1, one of the
most widely studied lncRNAs involved in cell cycle arrest,
downregulated in senescent cells. Knockdown of Malat1
blocks the progression of the cell cycle at the G1/S phase,
resulting in more senescence-like cells [173]. We already dis-
cussed as telomere erosion causes telomere shortening upon
each cell cycle and results in senescent cells. The lncRNA
telomeric repeat-containing RNA, TERRA, can base pair
with the RNA template of telomerase and can also bind to
the telomerase reverse transcriptase polypeptide to inhibit
telomerase activity [174, 175]. As a result, cells expressing
increased levels of TERRA become senescent [174, 175].
Interestingly, the structure and function of TERRA are con-
served among eukaryotes, rendering TERRA-mediated regu-
lation of telomerase a promising therapeutic strategy against
cancer and age-associated diseases.
Xia and colleagues have demonstrated that mesenchymal
stem cells (MSCs) isolated from aged mice display a reduced
proliferation and paracrine signalling, an increased oxidative
stress, and expression of lncRNA-p21 compared with MSCs
from younger mice. Silencing lncRNA-p21 in aged MSCs
using small interfering RNA (siRNA) enhances cell growth
and paracrine function and decreased oxidative stress
through Wnt/β-catenin pathway modulation [176]. The
regulatory effects of noncoding RNA molecules might be
therefore used to improve cardiac progenitor cell prolifer-
ation, cardiac cell differentiation, cardiac reprogramming,
and cardiac survival.
Accordingly, a large number of studies have focused their
attention principally on the possibility to modify stem cells,
in order to control their senescence or to activate their differ-
entiation potential using RNA molecules that directly act on
DNA by inducing epigenetic changes. As shown in MSCs,
histone deacetylase inhibitors produce an increase in the
acetylation of histones adjacent to the coding regions of
microRNAs, which engage in MSC aging [177]. MicroRNAs
expression changes during life-time and modulates the
senescence of adult stem cells by targeting genes involved in
DNA damage, epigenetic changes and metabolism. At the
same time, epigenetic mechanisms may regulate an enor-
mous number of microRNAs, mainly by DNA methylation
that represses gene activity by preventing the binding of
transcription factors to gene promoters or by favouring the
recruitment of chromatin-modifying enzymes [178]. Studies
of their expression and targets have the potential to supply
critical information on the aging process and its propagation
through cells, tissues, and organs [179]. The detection of
several circulating RNAs in biological samples has been cor-
related with different ages and some of them have been asso-
ciated with aging myopathy and epigenetic mechanism
underlying development and progression of cardiovascular
diseases [139, 180]. Thus, a combination of specific circulat-
ing lncRNAs and microRNAs may be a precious tool to esti-
mate the age-related deterioration of different organs and
age-related CVDs. Consequently, these RNA molecules have
been proposed as diagnostic/prognostic biomarkers and
therapeutic targets.
Since DNA methylation is intimately involved with dis-
eases and histone modification, it is not unreasonable to sug-
gest that the post-translational modifications of histones may
also be vital factors governing cell cycle, apoptosis, and
response to environmental cues [181]. Methylation of micro-
RNA promoters may be pivotal to determining the ability of
microRNA transcripts to be successfully produced. Dysregu-
lation of this event may induce the loss of functional micro-
RNAs and pathological developments in tissues or cellular
senescence [182]. Indeed, microRNAs are epigenetic regula-
tors of gene expression playing an essential role in the
post-transcriptional regulation and suppression or expres-
sion of many target genes [183]. For example, microRNAs
have been linked with the age-associated hypertrophic
growth of CMs, a typical feature of cardiac cell remodelling
in response to stresses [184]. CM hypertrophy leads molecu-
lar and morphological changes, including altered expression
of α-MHC, β-MHC, ANF and SERCA2, producing maladap-
tive cardiac hypertrophy and finally cardiac decompensation
[184]. The reactivation of this set of cardiac genes has been
found to be regulated by microRNAs.
It has been shown that aging influences circulating levels
of some microRNAs in animal models of physiological aging
as well in elderly subjects compared to younger ones [185,
186]. A large number of microRNAs have been described to
be differently expressed and to regulate different cell types
and pathways during cardiac aging [187]. Among the many
microRNAs upregulated with cardiac aging, there is miR-21
[187] that has a profibrotic effect and is highly expressed in
cardiac fibroblasts during injury. In addition, overexpression
of Ago1 and Ago2 synergistically induced miR-21 and
miR-21∗, suggesting a regulatory role for Ago proteins
[187]. Another microRNA involved in cardiac aging and
expressed in aged CMs is miR-22 [188, 189]. With age, the
expression of miR-22 has been found increased in the cardiac
tissue [190]. miR-22 overexpression is able to inhibit cell
cycle progression and is sufficient to provoke CM hypertro-
phy, and it may accelerate cardiac fibroblast senescence
[188]. The inhibition of miR-22 stimulates cardiac autoph-
agy, prevents maladaptive remodelling, and enhances cardiac
function postmyocardial infarction in older mice, but not in
younger ones [189].
Important evidences suggest a crucial role of micro-
RNA in CSCs too. miR-34 is an important regulator of
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senescence through its role in several pathways that
include cell cycle, telomere shortening, and DNA damage
response [190, 191]. The in vivo silencing of miR-34a by
injection of antisense oligonucleotides (antagomirs) can
partially rescue the cardiac aging phenotypes in mice and
promotes cardiac progenitor cell growth rate [190, 192].
Thus, the rescue of cardiac repair activity through miR-34
inhibition could be used for human heart disease treatment
[192]. This finding supports the potential of gene therapy
to reverse cardiac aging using microRNAs. However, as one
microRNA may have multiple targets, gene therapy targeting
microRNA may trigger undesirable side effects. An alterna-
tive approach is to identify the microRNA targets that medi-
ate cardiac aging responses and manipulate the specific target
genes as treatment strategy.
6. CSC Rejuvenation: Intrinsic and Extrinsic
Molecular Manipulation to Revert CSC Aging
All the evidences above detailed show that aging and cellular
senescence are a major hindrance to the endogenous regener-
ative efficacy of CSCs/CPCs. However, the persistence in
aged decompensated hearts of a population of functionally
competent CSCs with long telomeres [193] generates the
hypothesis that endogenous CSCs may be indeed rejuvenated
to regain robust regenerative potential. This population of
functional yet old CSCs lacks senescent markers, expresses
telomerase and cycling proteins, such as Ki67 [35, 36], and
displays the capacity to migrate to injured zones generating
a healthy progeny of young CMs. Indeed, as demonstrated
in old humans, a pool of CSCs dividing by asymmetric chro-
matid segregation seems to maintain a growth reserve and
self-renewing potential in the cardiac tissue, critical variables
for effective cardiac homeostasis and repair during aging
[193]. This evidence may correlate to epigenetic modifica-
tions in the longer telomeres of human CSCs with old intact
DNA that may account for the more effective maintenance of
chromosomal ends in this CSC pool [193, 194]. These
evidences postulate that nonsenescent and undamaged
CSCs in the heart may be the target of regenerative thera-
pies to improve cardiac performance with prolongation
and improvement of lifespan in the elderly [36].
On the other hand, it is expected that a better under-
standing of the metabolic pathways and molecular mecha-
nisms active in adult stem cells in old tissues may be
helpful to develop genetic approaches or drugs to preserve
their stemness potential during aging and to manipulate their
quiescence, self-renewal, and differentiation [2, 195]. Several
strategies able to decrease ROS levels, to restore or increase
telomerase activity and telomere length in order to delay
the natural aging process of the entire organism, have been
studied in the past decade. For example, mouse models of
telomere deficiency show an increase in age-related cardiac
hypertrophy and decompensation [100, 196], while mice
overexpressing telomerase present a nonpathologic cardiac
hypertrophy and a resistance to the acute ischemic insult
from myocardial infarction [197], demonstrating the impor-
tance of the telomere-telomerase system in cardiac cell aging
studies in order to promote their rejuvenation. Through its
cell cycle inhibition effects, p16INK4A is the major
regulator of self-renewal of various adult stem cell types
playing a role in the decreased efficacy of stem cell prolifer-
ation [198, 199]; it has been therefore the target of many
aging studies. Cells genetically modified to overexpress
p16INK4A display a growth arrest similarly observed in
senescent cells that typically show an elevated p16INK4A
expression [200, 201]. As cited above, its upregulation can
be induced by stress stimuli such as DNA damage and oxy-
gen radicals [199]. Since several studies have shown that
p16INK4A silencing may significantly delay cellular entry
into senescence [79, 202], Khatiwala and colleagues [203]
have knockdown this gene as a method to attempt
rejuvenation of aged human CPCs in order to promote
myocardial repair. They demonstrated that knockdown of
p16INK4A reverses the senescent phenotype and has a ben-
eficial antioxidant effect on aged human CPCs with a
decrease of ROS by approximately 50%. Because of ROS’s
role in the acceleration of cellular senescence, knockdown
of the p16INK4A gene may exert beneficial effects in
extending lifespan inducing cellular rejuvenation of the
aged human CPCs [203].
Bmi-1 is a member of the Polycomb repressor complex
1 that mediates gene silencing by regulating the chromatin
structure and is indispensable for self-renewal of both nor-
mal and cancer stem cells [204, 205]. Bmi-1 controls
self-renewal and cell cycle by regulating the tumor sup-
pressor proteins p16Ink4a and p14Arf [204, 205]. Further-
more, it has been shown that Bmi-1 prevents adult stem
cell aging, at least partly, by blocking expression of the
cyclin-dependent kinase inhibitor p16Ink4a [204, 205].
Additionally, Bmi-1 inhibits ROS-induced oxidative DNA
damage along with facilitating the overall DNA damage
response, contributing to maintaining genome integrity and
resistance to genotoxic therapeutic reagents. Therefore, dys-
regulation of the Bmi-1/p16Ink4a pathway is considered
key to the loss of tissue homeostasis and development of
associated degenerative diseases during aging. Not surpris-
ingly, Bmi-1 is also expressed in the hCSCs [118]. Impor-
tantly, the undifferentiated hCSCs from old donors exhibit
a lower level expression of Bmi-1 when compared to hCSCs
from young donors. hCSCs infected with a lentivirus consti-
tutively expressing Bmi-1, increased significantly the cloning
efficiency and BrdU incorporation of cloned hCSCs. Con-
versely, downregulation of Bmi-1 with specific si-RNA sig-
nificantly impaired cloning efficiency and proliferation of
the hCSCs, while increasing the expression of p16Ink4a
(our preliminary data).
Despite that, during the late adulthood, the heart main-
tains a functionally competent CSC compartment, the aged
cardiac phenotype produces an accumulation of senescent
CSCs. Many evidences have pointed to the possibility to
revert the senescent cardiac phenotype using growth factors
or cardioprotective molecules, fostering CSC physiological
turnover in order to maintain their stemness potential.
IGF-1 [37, 206], Pim-1 [91], Follistatin-like 1 [207, 208],
and growth differentiation factor 11 [208–210] are all
together examples of antiageing factors capable to induce
endogenous regeneration in the aged heart.
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The consequence of oxidative stress in the average life-
span of CSCs may be reverted by the administration of
IGF-1. This growth factor not only produces a decrease in
the oxidative stress in the cardiac tissue [37] but is able to
act on DNA damage repair by homologous recombination
[211]. Moreover, administration of IGF-1 in aged mice
models enhances phospho-Akt expression and the telome-
rase pathway, delaying cellular aging and death [37]. A
reduced phospho-Akt expression has been associated with
ageing and is now thought to act as a main modulator of tel-
omerase activity in the survival molecular signalling. Thus,
therapies aimed at stimulating Akt expression have been
shown to bypass some ageing effects [37]. The redox effector
protein-1 (Ref-1) is another important protein that plays an
essential role in DNA repair and redox regulation of several
transcription factors. Particularly, Ref-1 seems to maintain
the redox status and survival of adult CSCs. Gurusamy and
colleagues [4] have shown that Ref-1 inhibition robustly
induces the increase of intracellular ROS and the treatment
of CSCs with a low concentration of H2O2 seems to induce
Ref-1-mediated survival signalling through phosphorylation
of Akt. They have also shown that after H2O2 treatment in
Ref-1-inibited CSCs, the expression of cardiac differentiation
markers (Nkx2.5, MEF2C, and GATA4 and α-sarcomeric
actinin) was significantly elevated. Further, Ref-1 inhibition
seems to produce in CSCs an increased p53 expression lead-
ing to cell death and a decreased Akt phosphorylation.
Finally, Gurusamy and colleagues demonstrated that treat-
ment with the ROS scavenger N-acetyl-L-cysteine attenuates
oxidative phosphorylation and cardiac differentiation. Thus,
Ref-1 plays an important role in maintaining the redox status
of CSCs and protects them from oxidative injury-mediated
cell death and differentiation [4].
Another promising study is focused on the ex vivo
modification of CPCs using Pim-1 kinase for its potential
to alleviate cellular senescent characteristics. Mohsin and
colleagues [212] have used a lentivirus to overexpress
Pim-1 in CPCs isolated from a 68-year-old heart failure
patient. The Pim-1-modified CPCs have been transplanted
into an immunocompromised mouse model of myocardial
infarction showing enhanced persistence, survival, prolifer-
ation, and differentiation potential compared with the
older nonmodified counterpart. Pim-1 is cardioprotective
and able to rejuvenate CSC phenotypic and their functional
properties, restoring youthful telomeric length, enhancing
replicative capacity, and decreasing the levels of p16Ink4a
and p53 [212]. Concurrently, another elegant study provided
the evidence that nucleostemin (NS) expression is lower in
CPCs isolated from aged compared to young mice. Hari-
haran and colleagues [213] demonstrated that aged CPCs
engineered for NS expression preserved their stemness prop-
erties while deficiency of NS led to myocardial ageing due to
telomere shortening.
The ability to rejuvenate human cardiac progenitor
cells ex vivo by Pim-1 or NS modification is encouraging
proofs of concept for the combination of gene and stem
cell therapies to develop efficient CSC rejuvenation in
order to prevent and/or treat myocardial decompensation
as a result of cardiac aging.
7. Future Clinical Perspectives to Delay Cardiac
Aging Rejuvenating the Senescent
Human Heart
The average lifespan of the human population is increasing.
Since the vast majority of all the worldwide deaths occur
for cardiovascular diseases in a segment of population older
than 70 years, the prevalence of cardiovascular pathology
makes heart disease largely an elderly disease.
The aged myocardial tissue is characterized by several
pathological or physiological conditions including increased
ROS production and oxidative stress, loss of telomere/telo-
merase integrity, and telomere shortening (Figure 3).
Together, these processes contribute to the development of
a senescent phenotype in cardiac cells ensuing in heart tissue
homeostasis abnormalities leading to diastolic and systolic
dysfunctions in the aged myocardium. Cardiac tissue homeo-
stasis is mainly impaired by the accumulation in the extracel-
lular matrix of inflammatory cytokines which negatively
influences the behaviour of neighbouring cells. This phe-
nomenon compromises CSC function during aging leading
to an inadequate regenerative response and cardiac decom-
pensation. Concurrently, cellular lifespan may depend on a
mitotic clock and this phenomenon may have a pivotal role
in cardiac aging and in the attenuation of cell turnover in
the old myocardial tissue. Moreover, aging represents a
decline in cardioprotective systems affecting pathophysio-
logical cardiovascular pathways, a process that is a fertile
ground for the development of cardiomyopathy. As conse-
quence, a better insight into the mechanisms of cardiac
aging could lead to discover factors implicated in cardiac
pathophysiology on one side and on the other to improve
prevention strategies for aging-related human cardiovascu-
lar diseases.
As summarized in this review, nowadays, cardiovascular
research produced a significant number of studies display-
ing methodologies and therapeutic approaches to delay or
treat cardiac aging. These approaches could be able to
decrease ROS levels, as Gurusamy and colleagues [4] shown
using Ref-1, or may include gene therapy to modify the
levels of expression of several genes and proteins involved
in cardiac aging (i.e., p16INK4A, Bmi-1, and Akt). Despite
that future studies are required to evaluate the translational
potentials of cardiac stem cell therapy, the possibility to
manipulate these cells to express growth factors or cardio-
protective molecules (i.e., IGF-1, Pim-1, Follistatin-like 1,
and nucleostemin) may become an important goal to
develop strategies to fostering autologous CSC physiological
turnover in order to maintain their stemness potential, to
rejuvenate them, and to improve their beneficial regenerati-
ve/reparative properties.
Interestingly, centenarians may become a model of
successful ageing because they are less susceptible to car-
diovascular diseases and all ageing-related diseases [142,
214, 215]. Villa and colleagues have measured the serum
levels of BPIFB4 protein in subjects able to reach extreme
ages and in long-living individuals (LLIs) [216]. They
identified a variant in the BPIFB4 transcript downregu-
lated during aging [217]. Thus, the serum levels of BPIFB4
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could correlate with the ability to reach extreme ages and
with LLI health status [216]. BPIFB4 appears to have a
beneficial effect on cellular homeostasis, where its overex-
pression activates stress response (with upregulation of
heat shock proteins), and proteostasis (especially involved
in genomic integrity and activation of protein synthesis).
On the other hand, the possibility to study CSCs belong-
ing to centenarians may become relevant to detect hypo-
thetical different molecular mechanisms and biological
characteristics and compare them with our current knowl-
edge about CSCs. These studies may become a precious
source to definitively understand how to delay cardiac
aging rejuvenating the senescent human heart.
Overall, as most donors and in particular recipients in
need of CSC therapy are of older age and exhibit a disease
state, it is fundamental to acquire a better understanding of
the biology and regenerative potential of the endogenous
CSCs in order to design and develop better protocols and
interventions for the regeneration of functional contractile
mass following myocardial injury through the activation of
these regenerative cells in situ.
8. Conclusions
The present available evidence shows that the mammalian,
including the human, myocardium possesses an “aged”
CSC phenotype and this affects CSC self-renewal ability, dif-
ferentiation, and regenerative potential (Figure 4). Thus,
CSCs are not immortal. They undergo cellular aging in
response to a variety of physiological and pathological
demands. Nevertheless, the old myocardium preserves an
endogenous functionally competent CSC cohort which
appears to be resistant to the senescent phenotype occurring
with aging. The latter envisions the phenomenon of CSC age-
ing as a result of a stochastic and therefore reversible cell
autonomous process. Indeed, if CSC aging is really a sto-
chastic cell autonomous process, then the possibility to
rejuvenate the endogenous CSC population by stimulating
their growth and self-renewing could be concrete. On the
other hand, CSC aging could be a cell cycle-dependent
process, affecting all or most of the endogenous CSC pop-
ulation, with a consequent irreversible loss of CSC regen-
erative capacity with time. If the latter is correct, it is
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Figure 4: Schematic representation of the accumulation of “old” CSCs during cardiac homeostasis in aging and their impaired regenerative
response after injury when compared to “healthy” young CSCs.
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predictable that the loss of CSC regenerative capacity with
time progression is an inevitable phenomenon that cannot
be rescued by stimulating their growth, which would only
speed their progressive exhaustion. Moreover, to study the
epigenetic signatures of healthy old people, i.e., centenar-
ians, could be an important aspect to identify the role of
chromatin modifications and plasticity in the longevity
phenotype that seems to require a combination of stochas-
tic and nonstochastic events to modulate genetic substrates
leading to different outcomes [218]. It is possible that cen-
tenarians have a more powerful “engine” shaped by evolu-
tion and that environment, epigenetic system, and genetic
predisposition could be components influencing their CSC
pool preservation.
The determination of whether the aged phenotype of
the CSCs is reversible or irreversible has importance for
the future of myocardial regeneration. The majority of
the data currently available predict that the “aged” CSCs
can be rejuvenated and their properties reversed through
manipulating certain intrinsic and extrinsic factors. There-
fore, aged CSCs can be reintroduced back into the func-
tional CSC pool. However, to reach this goal, several
main questions remain to be answered: (a) Is the
self-renewing potential of the cycling competent hCSCs
isolated from an old heart similar or different from that
of cycling hCSCs isolated from a young and healthy
heart? What is the self-renewing potential of the clonal
hCSCs isolated from these two types of hearts? Is the
growth potential of cycling competent hCSCs from old
hearts diminished? If so, is there an inverse correlation
between cycling competent hCSC growth potential and
the fraction of aged hCSCs in the tissue? (b) Is the quan-
titative and qualitative differentiation potential of cycling
competent hCSCs constant or does it change as the frac-
tion of aged hCSCs increases? (c) Is the diminished
self-renewal and/or differentiation potential of the hCSCs
from the old/failing hearts due to a diminished cycling
or differentiation potential of these cells? Or, is it due to
a change in their pattern of cell division, which increases
the probability of producing a higher fraction of differen-
tiated cells at the expense of the self-renewal of the
hCSCs, as described below?
The answers to these and other similar questions will
clearly rule the path toward a solid evidence-based clinical
application of CSC rejuvenation strategies to prevent and
treat cardiovascular diseases in the elderly.
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